Category: Company Focus

Biotech Companies on the Rise For 2016

The biotechnology industry has been dominated by blue chip pharmaceutical companies like Celegne, Amgen, Novartis and Pfizer for long. But there are other biotech companies who are fast rising and may soon catch up with the giants. Biotech companies mostly grow as a result of developing new drugs and thereby diversifying their portfolio, or strategic acquisitions and mergers.  Here are the ones with the biggest potentials; Gilead Science (GILD) Though recognized as blue chip, Gilead’s growth seems to be taking a new path upward with the development of Harvoni and Sovaldi, hepatitis C treatment drugs. Ranked as 118th in...

Read More

Adamas Pharmaceuticals, Inc. (ADMS) Up Big

On a day when the DJIA was up over 1% respectively,  Adamas Pharmaceuticals, Inc. (ADMS), a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems, stole the show with an announcement that prompted an incredibly impressive 82.98% gain in just one day. The Announcement: Adamas Announces Positive Top-Line Phase 3 Results of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson’s Disease EMERYVILLE, Calif., Dec. 23, 2015 (GLOBE NEWSWIRE) — Adamas Pharmaceuticals, Inc. (ADMS) today announced that its Phase 3 EASE LID clinical trial evaluating the company’s investigational compound ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease met its primary endpoint.  Results from this randomized, placebo-controlled study showed a statistically significant reduction (p = 0.0009) in LID at 12 weeks for patients who received ADS-5102 versus placebo as assessed by the Unified Dyskinesia Rating Scale (UDysRS).  This represents a 23 percent reduction in LID for ADS-5102-treated patients compared to placebo.  The reduction in LID was maintained at 24 weeks (p = 0.0008), a key secondary analysis.  The company plans to present comprehensive data at an upcoming scientific conference. Get the full report here: Gains were held through out the day and finished in a flurry. Chalk the Company’s ADS-5102 drug up to the success board. ADMS still has long road...

Read More